{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:21:25Z","timestamp":1763018485578,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA23766"],"award-info":[{"award-number":["P01 CA23766"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1038\/s41409-022-01689-4","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T04:06:03Z","timestamp":1651032363000},"page":"1095-1100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant"],"prefix":"10.1038","volume":"57","author":[{"given":"Maria","family":"Sola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valkal","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meighan","family":"Palazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen E.","family":"Cavalier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean M.","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Maloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliet N.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Castro-Malaspina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0469-839X","authenticated-orcid":false,"given":"David","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0794-3226","authenticated-orcid":false,"given":"Parastoo B.","family":"Dahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann A.","family":"Jakubowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Landau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esperanza B.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2386-0850","authenticated-orcid":false,"given":"Roni","family":"Tamari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy A.","family":"Kernan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0032-6559","authenticated-orcid":false,"given":"James W.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna D.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9422-5766","authenticated-orcid":false,"given":"Doris M.","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"1689_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/sj.bmt.1705899","volume":"41","author":"VT Ho","year":"2008","unstructured":"Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant. 2008;41:229\u201337.","journal-title":"Bone Marrow Transplant"},{"key":"1689_CR2","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2016-02-694943","volume":"127","author":"S Arai","year":"2016","unstructured":"Arai S. Long-awaited news for hepatic veno-occlusive disease. Blood. 2016;127:1630\u20131.","journal-title":"Blood."},{"key":"1689_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255\u201367.","journal-title":"Ann Intern Med"},{"key":"1689_CR4","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/bmt.2015.52","volume":"50","author":"M Mohty","year":"2015","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015;50:781\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"1689_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/bjh.13215","volume":"168","author":"E Carreras","year":"2015","unstructured":"Carreras E. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol. 2015;168:481\u201391.","journal-title":"Br J Haematol"},{"key":"1689_CR6","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","volume":"102","author":"M Wadleigh","year":"2003","unstructured":"Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102:1578\u201382.","journal-title":"Blood."},{"key":"1689_CR7","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740\u201353.","journal-title":"N Engl J Med"},{"key":"1689_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","volume":"16","author":"JA Coppell","year":"2010","unstructured":"Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16:157\u201368.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1689_CR9","doi-asserted-by":"publisher","first-page":"975","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00002","volume":"128","author":"JH Essell","year":"1998","unstructured":"Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:975\u201381.","journal-title":"Ann Intern Med"},{"key":"1689_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N","volume":"64","author":"K Ohashi","year":"2000","unstructured":"Ohashi K, Tanabe J, Watanabe R, Tanaka T, Sakamaki H, Maruta A, et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol. 2000;64:32\u201338.","journal-title":"Am J Hematol"},{"key":"1689_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/sj.bmt.1703342","volume":"29","author":"SH Park","year":"2002","unstructured":"Park SH, Lee MH, Lee H, Kim HS, Kim K, Kim WS, et al. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:137\u201343.","journal-title":"Bone Marrow Transplant"},{"key":"1689_CR12","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1182\/blood-2001-12-0159","volume":"100","author":"T Ruutu","year":"2002","unstructured":"Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood. 2002;100:1977\u201383.","journal-title":"Blood."},{"key":"1689_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5500\/wjt.v2.i2.27","volume":"2","author":"DK Cheuk","year":"2012","unstructured":"Cheuk DK. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: prophylaxis and treatment controversies. World J Transplant. 2012;2:27\u201334.","journal-title":"World J Transplant"},{"key":"1689_CR14","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41409-019-0705-z","volume":"55","author":"M Mohty","year":"2020","unstructured":"Mohty M, Malard F, Abecasis M, Aerts E, Alaskar AS, Aljurf M, et al. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplant. 2020;55:485\u201395.","journal-title":"Bone Marrow Transplant"},{"key":"1689_CR15","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1182\/blood.V79.11.2834.bloodjournal79112834","volume":"79","author":"M Attal","year":"1992","unstructured":"Attal M, Huguet F, Rubie H, Huynh A, Charlet JP, Payen JL, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood. 1992;79:2834\u201340.","journal-title":"Blood."},{"key":"1689_CR16","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/sj.bmt.1704087","volume":"31","author":"DL Forrest","year":"2003","unstructured":"Forrest DL, Thompson K, Dorcas VG, Couban SH, Pierce R. Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. Bone Marrow Transplant. 2003;31:1143\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"1689_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1600-0609.1991.tb01859.x","volume":"47","author":"L Marsavila","year":"1991","unstructured":"Marsavila L, Gorin NC, Laporte JP, Labopin M, Dupuymontbrun MC, Fouillard L, et al. Prophylactic heparin does not prevent liver venoocclusive disease following autologous bone-marrow transplantation. Eur J Haematol. 1991;47:346\u201354.","journal-title":"Eur J Haematol"},{"key":"1689_CR18","first-page":"185","volume":"18","author":"J Rosenthal","year":"1996","unstructured":"Rosenthal J, Sender L, Secola R, Killen R, Millerick M, Murphy L, et al. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Bone Marrow Transplant. 1996;18:185\u201391.","journal-title":"Bone Marrow Transplant"},{"key":"1689_CR19","first-page":"3742","volume":"88","author":"L Feldman","year":"1996","unstructured":"Feldman L, Milovic V, Jaimovich G, Requejo A, Altclas J, Brioschi S. Prevention of hepatic veno-occlusive disease after bone morrow transplantation (BMT) by continuous infusion of low-dose heparin. Blood. 1996;88:3742\u20133742.","journal-title":"Blood."},{"key":"1689_CR20","first-page":"3599","volume":"92","author":"E Carreras","year":"1998","unstructured":"Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood. 1998;92:3599\u2013604.","journal-title":"Blood."},{"key":"1689_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/sj.bmt.1702854","volume":"27","author":"M Simon","year":"2001","unstructured":"Simon M, Hahn T, Ford LA, Anderson B, Swinnich D, Baer MR, et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transplant. 2001;27:627\u201333.","journal-title":"Bone Marrow Transplant"},{"key":"1689_CR22","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1097\/00043426-200212000-00013","volume":"24","author":"U Reiss","year":"2002","unstructured":"Reiss U, Cowan M, McMillan A, Horn B. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol. 2002;24:746\u201350.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1689_CR23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/sj.bmt.1705297","volume":"37","author":"H Imran","year":"2006","unstructured":"Imran H, Tleyjeh IM, Zirakzadeh A, Rodriguez V, Khan SP. Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. Bone Marrow Transplant. 2006;37:677\u201386.","journal-title":"Bone Marrow Transplant"},{"key":"1689_CR24","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1689_CR25","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"WM Assoc","year":"2013","unstructured":"Assoc WM. World Medical Association Declaration of Helsinki ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","journal-title":"JAMA"},{"key":"1689_CR26","doi-asserted-by":"publisher","first-page":"4552","DOI":"10.1182\/blood-2007-06-093880","volume":"110","author":"AA Jakubowski","year":"2007","unstructured":"Jakubowski AA, Small TN, Young JW, Kernan NA, Castro-Malaspina H, Hsu KC, et al. T cell-depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood. 2007;110:4552\u20139.","journal-title":"Blood."},{"key":"1689_CR27","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.bbmt.2011.08.017","volume":"18","author":"CA Keever-Taylor","year":"2012","unstructured":"Keever-Taylor CA, Devine SM, Soiffer RJ, Mendizabal A, Carter S, Pasquini MC, et al. Characteristics of CliniMACS(R) System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. Biol Blood Marrow Transplant. 2012;18:690\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1689_CR28","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.bbmt.2013.02.018","volume":"19","author":"UD Bayraktar","year":"2013","unstructured":"Bayraktar UD, de Lima M, Saliba RM, Maloy M, Castro-Malaspina HR, Chen J, et al. Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2013;19:898\u2013903.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1689_CR29","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1016\/j.bbmt.2013.12.212","volume":"20","author":"JN Barker","year":"2014","unstructured":"Barker JN, Ponce DM, Dahi P, Devlin S, Evans K, Lubin M, et al. Double-unit cord blood (CB) transplantation combined with haplo-identical CD34+cells results in 100% CB engraftment with enhanced myeloid recovery. Biol Blood Marrow Transplant. 2014;20:S138\u2013S139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1689_CR30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/bmt.2013.107","volume":"49","author":"T Ruutu","year":"2014","unstructured":"Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant. 2014;49:168\u201373.","journal-title":"Bone Marrow Transplant"},{"key":"1689_CR31","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.bbmt.2015.01.024","volume":"21","author":"S Harnicar","year":"2015","unstructured":"Harnicar S, Ponce DM, Hilden P, Zheng JT, Devlin SM, Lubin M, et al. Intensified mycophenolate mofetil dosing and higher mycophenolic acid trough levels reduce severe acute graft-versus-host disease after double-unit cord blood transplantation. Biol Blood Marrow Transplant. 2015;21:920\u20135.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1689_CR32","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","volume":"97","author":"PA Rowlings","year":"1997","unstructured":"Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97:855\u201364.","journal-title":"Br J Haematol"},{"key":"1689_CR33","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.bbmt.2007.08.047","volume":"13","author":"E Copelan","year":"2007","unstructured":"Copelan E, Casper JT, Carter SL, van Burik JA, Hurd D, Mendizabal AM, et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant. 2007;13:1469\u201376.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1689_CR34","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","volume":"44","author":"RJ Jones","year":"1987","unstructured":"Jones RJ, Lee KSK, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venoocclusive disease of the liver following bone-marrow transplantation. Transplantation. 1987;44:778\u201383.","journal-title":"Transplantation."},{"key":"1689_CR35","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1200\/JCO.1993.11.9.1729","volume":"11","author":"SI Bearman","year":"1993","unstructured":"Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, Mcdonald GB. Venoocclusive disease of the liver - development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol. 1993;11:1729\u201336.","journal-title":"J Clin Oncol"},{"key":"1689_CR36","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","volume":"100","author":"PG Richardson","year":"2002","unstructured":"Richardson PG, Murakami C, Jin ZZ, Warren D, Momtaz P, Hoppensteadt D, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100:4337\u201343.","journal-title":"Blood."},{"key":"1689_CR37","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.bbmt.2010.02.009","volume":"16","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010;16:1005\u201317.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1689_CR38","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127:1656\u201365.","journal-title":"Blood."},{"key":"1689_CR39","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.bbmt.2017.03.008","volume":"23","author":"PG Richardson","year":"2017","unstructured":"Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, et al. Defibrotide for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome: interim results from a treatment IND study. Biol Blood Marrow Transplant. 2017;23:997\u20131004.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1689_CR40","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bjh.15267","volume":"181","author":"NA Kernan","year":"2018","unstructured":"Kernan NA, Grupp S, Smith AR, Arai S, Triplett B, Antin JH, et al. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome. Br J Haematol. 2018;181:816\u201327.","journal-title":"Br J Haematol"},{"key":"1689_CR41","first-page":"CD009311","volume":"5","author":"DK Cheuk","year":"2015","unstructured":"Cheuk DK, Chiang AK, Ha SY, Chan GC. Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2015;5:CD009311.","journal-title":"Cochrane Database Syst Rev"},{"key":"1689_CR42","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bbmt.2013.10.014","volume":"20","author":"T Ruutu","year":"2014","unstructured":"Ruutu T, Juvonen E, Remberger M, Remes K, Volin L, Mattsson J, et al. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biol Blood Marrow Transplant. 2014;20:135\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1689_CR43","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","volume":"22","author":"JH Dalle","year":"2016","unstructured":"Dalle JH, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant. 2016;22:400\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1689_CR44","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/sj.bmt.1703025","volume":"27","author":"F Moscardo","year":"2001","unstructured":"Moscardo F, Sanz GF, de La Rubia J, Jimenez C, Saavedra S, Regadera A, et al. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection. Bone Marrow Transplant. 2001;27:983\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1689_CR45","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1097\/00007890-199112000-00015","volume":"52","author":"RJ Soiffer","year":"1991","unstructured":"Soiffer RJ, Dear K, Rabinowe SN, Anderson KC, Freedman AS, Murray C, et al. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 1991;52:1014\u20139.","journal-title":"Transplantation."}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01689-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01689-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01689-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T18:10:21Z","timestamp":1666375821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01689-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1689"],"URL":"https:\/\/doi.org\/10.1038\/s41409-022-01689-4","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2022,4,27]]},"assertion":[{"value":"30 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DMP has served as advisory board member for Evive Biotechnology (Shanghai) Ltd (formerly Generon [Shanghai] Corporation Ltd), Kadmon Corporation, CareDx, Ceramedix, and Incyte Corporation, and receives research funding from Incyte Corporation. Otherwise, the authors have no relevant conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}